Table 1.
Patient demographic information, diagnosis of M component disease, therapy, treatment phase, and co-morbidity. Abbreviations: VRD: velcade/lenalidomide/dexamethasone; KRD: kyprolis/lenalidomide/dexamethasone; Rev: lenalidomide; Dex: dexamethasone; Dara: daratumumab Rev/Dex: revlimid/dexamethasone; MM: multiple myeloma; POEMS: POEMS syndrome (osteosclerotic myeloma); MRD: minimal residual disease.
| Patient ID | Age | Covid Ab | Diagnosis | MM Stage (R-ISS) | Disease State When Tested COVID-19 Positive | Prior Chemo Therapy | Active Chemo Therapy When Tested COVID-19 Positive (Yes/No/Maintenance) | Stem Cell Transplant before COVID-19 Infection (Yes/No) | Co-Morbidities | Hospitalization Due to COVID-19 Infection | Death Due to COVID-19 Infection | Bamlanivimab (Yes/No) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 58 | Negative | MM | Stage I | Persistent disease (3.9% plasma cells) | Cytoxan/Lenalidomide/Dex, Dara | No | No | T2DM, HLD | No | No | No |
| 2 | 58 | NA | MM | Stage I | In remission | VRD | No | Yes | CHF, HTN, T2DM | No | No | No |
| 3 | 63 | NA | MM | Unknown | In remission | Bortezomib/Rev/Dex | No | Yes | Rheumatiod Arthritis | no | No | No |
| 4 | 74 | NA | MM | Unknown | Persistent disease (5–10% plasma cells) | Dara/Pomalidomide/Dex | No | No | Bladder cancer: s/p local therapy; prostate cancer: s/p radiation therapy | No | No | No |
| 5 | 69 | Negative | MM | Stage I | MRD (<5% plasma cells) | VRD | Yes (pomalidomide) | No | HTN, basal cell carcinoma, GERD, follicular lymphoma (grade II) | Yes (intubation) | No | No |
| 6 | 46 | Postive | MM | Stage I | In remsssion | KRD | Maintenance (Lenalidomide) |
Yes | None | No | No | Yes |
| 7 | 71 | NA | MM | Unknown | Newly diagnosed (30% plasma cells) | Not started yet | No | No | HTN | No | No | No |
| 8 | 66 | NA | MM | Stage II | In remission | VRD | No | Yes | None | No | No | Yes |
| 9 | 52 | NA | MM | Unknown | In remission | VRD | Maintenance (Lenalidomide) |
Yes | Breast cancer S/P mastectomy and adjuvant chemo; thyroid carcinoma s/p total thyroidectomy | No | No | Yes |
| 10 | 60 | Negative | MM | Stage I | Residual disease (5% plasma cells) | VRD | Maintenance (Lenalidomide) |
Yes | None | No | No | No |
| 11 | 55 | NA | MM | Unknown | Residual disease (4% plasma cells) | VRD, Dara | Yes (Dara/Kyprolis/Dex) | Yes | None | No | No | No |
| 12 | 63 | NA | MM | Unknown | In remission | VRD, Dara | Maintenance (Lenalidomide) |
Yes | None | No | No | No |
| 13 | 60 | NA | MM | Unknown | In remission | Melphalan | Maintenance (Lenalidomide) |
Yes | HTN, T2DM, end stage renal disease | No | No | Yes |
| 14 | 74 | NA | MM | Stage II | Residual disease (1% plasma cells) | VRD | Yes (Dara/Len/Dex) | No | CVA, HTN, HLD, T2DM | No | No | Yes |
| 15 | 71 | Postive | MM | Unknown | In remission | KRD | Yes (KRD) | No | DCIS s/p lympectomy | No | No | Yes |
| 16 | 54 | NA | MM | Stage I | In remission | VRD, Dara | Maintenance (Lenalidomide) |
Yes | HTN | No | No | No |
| 17 | 49 | Positive | MM | Stage III | Residual disease (2% plasma cells) | VRD | No | No | HTN | No | No | No |
| 18 | 35 | NA | POEMS | Unknown | In remission | Rev/Dex | No | Yes | Chronic inflammatory demyelinating polyneuropathy | No | No | Yes |
| 19 | 63 | Positive | MM | Unknown | In remission | Velcade/Dex/Dara | No | Yes | HTN | No | No | No |
| 20 | 50 | Positive | MM | Stage II | In remission | VRD, Dara | Maintenance (Lenalidomide) |
Yes | Athritis | No | No | No |
| 21 | 61 | NA | MM | Stage II | Near complete remission | KRD | Maintenance (Lenalidomide) |
Yes | None | No | No | No |
| 22 | 71 | Positive | MM | Stage I | In remission | VRD | Yes (Rev/Dex) | No | Osteoarthritis | No | No | No |
| 23 | 59 | NA | Amyloidosis | Unknown | Progressive (on onpattro) | None | None | No | End stage infiltrative cardiomyopathy | No | No | No |
| 24 | 81 | Positive | MM | Stage III | Residual disease (unknown plasma cell %) | Ninlaro/Rev/Dex, Dara | Yes (Ninlaro/Rev/Dex) | No | None | Yes | No | No |
| 25 | 55 | NA | MM | Stage II | MRD (0.5% plasma cells) | VRD | Maintenance (Lenalidomide) |
Yes | None | No | No | No |
| 26 | 64 | Positive | POEMS | Stage II | In remission | Rev/Dex | Maintenance (Lenalidomide) |
Yes | None | Yes | No | No |
| 27 | 56 | NA | MM | Stage III | Near complete remission | VRD | None | No | None | No | No | No |
| 28 | 82 | Negative | MM | Unknown | In remission | Thalidomide/ Dex, Daratumumab | Blenrep | Yes | CM/HF s/p pacemaker, CAD s/p stents, stage 3 CKD | Yes | No | Yes |
| 29 | 58 | Positive | MM | Stage III | In remission | KRD | Maintenance (Lenalidomide) |
Yes | RCC | Yes | No | Yes |
| 30 | 67 | Positive | MM | Stage II | Persistent disease (6% plasma cells) | Dara-VRD | Yes (Dara-VRD) | NO | None | Yes | No | Yes |
| 31 | 55 | NA | POEMS | Unknown | Low level disease | Rev/Dex | Yes (Rev/Dex) | No | None | Yes | No | No |
| 32 | 35 | NA | MM (IgD type) | Stage I | MRD (0.3% plasma cells) | VRD | Maintenance (Lenalidomide) |
Yes | None | Yes | No | No |
| 33 | 80 | Positive | MM | Stage II | Persistent disease (unknown plasma cell percentage) | Ninlaro/Rev/Dex, Dara | Yes (Dara/Vel/dex) | No | Multi-organ system AL amyloidosis | Yes | Yes | No |
| 34 | 82 | NA | MM | Stage III | Persistent disease (unknown plasma cell percentage) | Cytoxan/Kyprolis/Dex | Yes (Cytoxan/Kyprolis/Dex) | Yes | CHF | Yes | Yes | No |